StockNews.com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS) from a sell rating to a hold rating in a research note released on Friday morning.

Several other research analysts have also recently weighed in on ATOS. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Monday, August 12th. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th.

Atossa Therapeutics Stock Performance

NASDAQ:ATOS opened at $1.45 on Friday. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31. The stock has a market cap of $182.35 million, a price-to-earnings ratio of -6.04 and a beta of 1.20. The business has a fifty day moving average of $1.42 and a 200-day moving average of $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts predict that Atossa Therapeutics will post -0.22 EPS for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ATOS. Vanguard Group Inc. boosted its position in shares of Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the period. Virtu Financial LLC acquired a new position in shares of Atossa Therapeutics in the 1st quarter valued at $151,000. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics in the 1st quarter valued at $72,000. Bank of New York Mellon Corp boosted its position in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the period. Finally, Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics in the 2nd quarter valued at $161,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.